NCT06345183 2025-11-06
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
Bristol-Myers Squibb
Completed
Clinical Trials
6 trialsNCT06771674 2025-09-09
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Hookipa Biotech GmbH
Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT04555603 2023-11-21
Axitinib Therapy Management Study
Pfizer
Withdrawn
NCT05611229 2023-04-06
Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden
Novartis
Completed
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown